Claims
- 1. A drug delivery system, comprising a lapachone or a prodrug thereof incorporated in a biocompatible polymer.
- 2. The system of claim 1, wherein the lapachone or prodrug thereof is admixed with the polymer.
- 3. The system of claim 1, wherein the system comprises an implant.
- 4. The system of claim 3, wherein the implant is a millirod dimensioned to position two radiation seeds a predetermined distance apart.
- 5. The system of claim 1, wherein the system comprises microparticles.
- 6. The system of claim 1, wherein the system comprises nanoparticles.
- 7. The system of claim 1, wherein the lapachone or prodrug thereof is provided as an inclusion complex with hydroxypropyl β-cyclodextrin.
- 8. The system of claim 1, wherein the lapachone has a structure of Formula I or II:
- 9. The system of claim 1, wherein the lapachone is β-lapachone.
- 10. The system of claim 1, wherein the polymer is biodegradable.
- 11. The system of claim 1, wherein the polymer comprises one or more of poly(lactic-co-glycolic acid) (PLGA), poly(lactic acid) (PLA), polyethylene glycol (PEG), polysebacic acid (PSA), or a polyanhydride.
- 12. An inhaler comprising microparticles according to claim 5.
- 13. A method of inhibiting proliferation of a cancerous cell in a patient, comprising administering to the patient the drug delivery system of claim 1.
- 14. The method of claim 13, wherein the cell overexpresses NQO1.
- 15. The method of claim 14, wherein the cell is a lung cancer cell, a breast cancer cell, or a prostate cancer cell.
- 16. The method of claim 15, wherein the cell is a non-small cell lung cancer cell.
- 17. The method of claim 16, wherein the system is delivered to the patient by inhalation of microspheres comprising a lapachone or a prodrug thereof and a biocompatible polymer.
- 18. The method of claim 13, wherein the cell is a prostate cancer cell and the system is delivered to the patient by implanting radioactive seeds spaced apart by at least one polymeric millirod comprising a lapachone or a prodrug thereof and a biocompatible polymer.
- 19. A system of claim 1, wherein a therapeutic agent, a diagnostic agent, an imaging agent, or an adjuvant is also incorporated in the polymer.
- 20. A lapachone or a prodrug thereof complexed with a β-cyclodextrin.
- 21. The lapachone of claim 20, wherein the β-cyclodextrin is a hydroxyalkyl β-cyclodextrin.
- 22. The lapachone of claim 20, wherein the β-cyclodextrin is a hydroxypropyl β-cyclodextrin.
- 23. A pharmaceutical formulation comprising the lapachone or prodrug thereof of claim 20.
- 24. A method of administering a lapachone or a prodrug thereof to a patient, comprising administering to the patient the lapachone of claim 20.
- 25. The lapachone of claim 20, wherein the lapachone has a structure of Formula I or II:
- 26. The lapachone of claim 20, wherein the lapachone is β-lapachone.
- 27. A kit comprising a lapachone or a prodrug thereof, a β-cyclodextrin, and instructions for combining the lapachone and β-cyclodextrin to form a complex and administering the complex to a patient.
- 28. A kit comprising at least two radioactive seeds, at least one millirod according to claim 4, and instructions for administering the seeds and millirod to a patient.
RELATED APPLICATION
[0001] This application claims the benefit of, and incorporates by reference, the entire disclsoure of U.S. Provisional Patent Application No. 60/374693, filed Apr. 23, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60374693 |
Apr 2002 |
US |